Perspectives
Analytics show super spenders account for nearly 10% of total drug spend
Studies on members with drug costs over $250,000 yield predictive modeling data
February 21, 2021Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
For many specialty conditions, nearly 90% of the total cost of care can come from drugs. That’s why Prime’s expertise at drug management is so important in controlling costs.
This study categorized and described trends in the medical conditions accounting for these member’s extraordinary drug expense.
This study contributes to Prime’s understanding of which drugs, conditions, and other factors can result in drug super spenders. It contributes to Prime’s ability to identify such members early by predictive modeling, and strategies to improve management of high cost specialty drugs. Integrated pharmacy claims analysis helps to confirm effectiveness of clinical programs and to identify additional opportunities.
Related news
Perspectives
September 25, 2023
Specialty Drug Pipeline Quarterly Update: September 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
September 25, 2023
Traditional Drug Pipeline Quarterly Update: September 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…
Perspectives
September 25, 2023
Gene/Cell Therapy Quarterly Update: September 2023
This quarterly pipeline wrap-up provides a review of newly approved gene and cell…